

## **First IOPTiMate™ System Procedures Sale in Romania**

**TEL AVIV (April 21, 2015)** - BioLight Life Sciences Investments Ltd. (**TASE: BOLT, OTCQX: BLGTY**), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced the first sale of the IOPTiMate™ system procedures to a private medical center located in Romania.

The IOPTiMate™ system is based on CO<sub>2</sub> laser technology that enables the performance of a unique filtration surgery to treat glaucoma without penetrating the inner part of the eyeball, thus allowing for substantial reductions in post-operative complications and use of eye drops compared with alternatives.

The Pay Per Procedure selling model further expands the company's selling capabilities and opportunities of the IOPTiMate™ system, and enable the engagement with additional potential clients for which this the Pay Per Procedure addresses their local market needs.

The company has also recently announced first sales of the IOPTiMate™ system in Hong Kong, Poland and Hungary.